CI Pulmonology CI TeamLaunch Lead
US COPD Competitive Intelligence
The COPD maintenance fight has moved past the inhaler. Two 2024 approvals, ensifentrine and dupilumab, opened the first genuinely novel mechanisms in a decade and split the market into an inhaler base and a biology-defined add-on tier.